FI3339865T3 - - Google Patents

Download PDF

Info

Publication number
FI3339865T3
FI3339865T3 FI17203178T FI17203178T FI3339865T3 FI 3339865 T3 FI3339865 T3 FI 3339865T3 FI 17203178 T FI17203178 T FI 17203178T FI 17203178 T FI17203178 T FI 17203178T FI 3339865 T3 FI3339865 T3 FI 3339865T3
Authority
FI
Finland
Prior art keywords
jcv
sample
subject
amount
hpvlp
Prior art date
Application number
FI17203178T
Other languages
English (en)
Finnish (fi)
Other versions
FI3339865T5 (fi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44305841&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI3339865(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Application granted granted Critical
Publication of FI3339865T3 publication Critical patent/FI3339865T3/fi
Publication of FI3339865T5 publication Critical patent/FI3339865T5/fi

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983Viruses
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854Immunoglobulins
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01DNA viruses
    • G01N2333/025Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00Immunoassays for the detection of microorganisms
    • G01N2469/20Detection of antibodies in sample from host which are directed against antigens from microorganisms
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/50Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
FIEP17203178.3T 2010-01-11 2011-01-11 Jc-viruksen vasta-aineiden määritys FI3339865T5 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29404810P 2010-01-11 2010-01-11
US31619310P 2010-03-22 2010-03-22

Publications (2)

Publication Number Publication Date
FI3339865T3 true FI3339865T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2022-11-30
FI3339865T5 FI3339865T5 (fi) 2023-04-15

Family

ID=44305841

Family Applications (2)

Application Number Title Priority Date Filing Date
FIEP22191259.5T FI4152004T3 (fi) 2010-01-11 2011-01-11 Jc-viruksen vasta-aineiden määritys
FIEP17203178.3T FI3339865T5 (fi) 2010-01-11 2011-01-11 Jc-viruksen vasta-aineiden määritys

Family Applications Before (1)

Application Number Title Priority Date Filing Date
FIEP22191259.5T FI4152004T3 (fi) 2010-01-11 2011-01-11 Jc-viruksen vasta-aineiden määritys

Country Status (27)

Country Link
US (2) US9316641B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (4) EP3339865B9 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (2) JP5946218B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR101877576B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN102906278A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2011203815B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR112012017014B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2784137A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (2) CY1119972T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (3) DK2524060T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (3) ES3012733T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (2) FI4152004T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HR (3) HRP20180356T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (3) HUE060312T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN2012DN06139A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LT (3) LT4152004T (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ME (1) ME03026B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX341991B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO2524060T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ600681A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (3) PL4152004T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (3) PT2524060T (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RS (3) RS66509B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SG (2) SG10201500079YA (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (3) SI2524060T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SM (3) SMT202200445T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2011085369A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2536915T5 (es) 2005-04-04 2023-03-01 Biogen Ma Inc Métodos y productos para evaluar una respuesta inmunitaria a una proteína terapéutica
EP2676967B1 (en) 2006-02-28 2019-08-14 Biogen MA Inc. Methods of treating inflammatory and autoimmune diseases with natalizumab
EP3360900A1 (en) 2006-03-03 2018-08-15 Biogen MA Inc. Methods of treating inflammatory and autoimmune diseases with natalizumab
AU2010303156B2 (en) 2009-10-11 2016-02-04 Biogen Ma Inc. Anti-VLA-4 related assays
US11287423B2 (en) 2010-01-11 2022-03-29 Biogen Ma Inc. Assay for JC virus antibodies
CN102906278A (zh) 2010-01-11 2013-01-30 比奥根艾迪克Ma公司 用于jc病毒抗体的测定
HUE043339T2 (hu) * 2011-05-31 2019-08-28 Biogen Ma Inc Módszer a PML kockázatának megállapítására
EP2791162A2 (en) * 2011-12-12 2014-10-22 Janssen Diagnostics BVBA Polyomavirus peptide sequences
WO2013158674A1 (en) * 2012-04-16 2013-10-24 Board Of Regents, The University Of Texas System Detection of extracellular jcv micrornas
WO2013192100A1 (en) 2012-06-18 2013-12-27 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods and compositions for detecting jc virus
WO2014102399A1 (en) 2012-12-31 2014-07-03 Neurimmune Holding Ag Recombinant human antibodies for therapy and prevention of polyomavirus-related diseases
US9949671B2 (en) 2013-03-13 2018-04-24 Orthoaccel Technologies, Inc. Diagnostic mouthpieces
US10119976B2 (en) 2013-05-28 2018-11-06 Biogen Ma Inc. Method of assessing risk of PML
WO2015131078A1 (en) * 2014-02-27 2015-09-03 Biogen Ma Inc. Method of assessing risk of pml
MA40985A (fr) 2014-11-17 2017-09-26 Biogen Ma Inc Méthodes de traitement de la sclérose en plaques
IT201600083859A1 (it) * 2016-08-09 2018-02-09 Univ Degli Studi Di Ferrara Immunosaggio per l’identificazione di anticorpi contro il virus Polioma JC (JCPyV) mediante l’uso di peptidi sintetici.
WO2019169317A1 (en) * 2018-03-02 2019-09-06 Stueve Olaf Methods and compositions for treating natalizumab-associated progressive multifocal encephalopathy

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4235601A (en) 1979-01-12 1980-11-25 Thyroid Diagnostics, Inc. Test device and method for its use
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4517288A (en) 1981-01-23 1985-05-14 American Hospital Supply Corp. Solid phase system for ligand assay
US4703017C1 (en) 1984-02-14 2001-12-04 Becton Dickinson Co Solid phase assay with visual readout
CA1291031C (en) 1985-12-23 1991-10-22 Nikolaas C.J. De Jaeger Method for the detection of specific binding agents and their correspondingbindable substances
US5763262A (en) 1986-09-18 1998-06-09 Quidel Corporation Immunodiagnostic device
ATE195022T1 (de) 1987-04-27 2000-08-15 Unilever Nv Spezifische bindungstestverfahren
US4943522A (en) 1987-06-01 1990-07-24 Quidel Lateral flow, non-bibulous membrane assay protocols
US5120643A (en) 1987-07-13 1992-06-09 Abbott Laboratories Process for immunochromatography with colloidal particles
US4818677A (en) 1987-12-03 1989-04-04 Monoclonal Antibodies, Inc. Membrane assay using focused sample application
AU2684488A (en) 1988-06-27 1990-01-04 Carter-Wallace, Inc. Test device and method for colored particle immunoassay
US5221616A (en) 1988-07-15 1993-06-22 Quidel Corporation Prevention of spontaneous complement activation in mammalian biological fluids
US5118630A (en) 1988-11-04 1992-06-02 Quidel Corporation Method for determining periodic infertility in females
US6352862B1 (en) 1989-02-17 2002-03-05 Unilever Patent Holdings B.V. Analytical test device for imuno assays and methods of using same
US6033665A (en) 1989-09-27 2000-03-07 Elan Pharmaceuticals, Inc. Compositions and methods for modulating leukocyte adhesion to brain endothelial cells
US5084828A (en) 1989-09-29 1992-01-28 Healthtech Services Corp. Interactive medication delivery system
US5252496A (en) 1989-12-18 1993-10-12 Princeton Biomeditech Corporation Carbon black immunochemical label
US5096837A (en) 1990-02-08 1992-03-17 Pacific Biotech, Inc. Immunochromatographic assay and method of using same
US5223220A (en) 1990-03-27 1993-06-29 Pacific Biotech, Inc. Solid phase immunoassay device and method of making same
US5118428A (en) 1990-11-13 1992-06-02 Quidel Method to remove red blood cells from whole blood samples
DE4139840B4 (de) 1990-12-04 2005-06-02 Quidel Corp., San Diego Antigen-Zubereitung zum Nachweis von H. pylori
WO1992012428A1 (en) 1991-01-11 1992-07-23 Quidel Corporation A one-step lateral flow nonbibulous assay
US5213796A (en) 1991-05-06 1993-05-25 Dana Farber Cancer Institute Assay for polyomavirus in humans and uses thereof
US5225328A (en) 1991-05-30 1993-07-06 Quidel Corporation Stable alkaline phosphatase compositions with color enhancement and their use in assays
US5686315A (en) 1991-06-14 1997-11-11 Quidel Corporation Assay device for one step detection of analyte
EP0646179A4 (en) 1992-02-04 1996-10-02 Quidel Corp PROCESS FOR SIMPLIFIED EXTRACTION OF BACTERIAL ANTIGENS USING DEHYDRATE REAGENTS.
US5541069A (en) 1992-02-28 1996-07-30 Quidel Corporation Assay having improved dose response curve
EP0630475B1 (en) 1992-03-10 2000-09-06 Quidel Corporation Red blood cell separation means for specific binding assays
NZ261259A (en) 1993-01-12 1996-12-20 Biogen Inc Humanised recombinant anti-vla4 antibody and diagnostic compositions and medicaments
US5415994A (en) 1993-08-02 1995-05-16 Quidel Corporation Lateral flow medical diagnostic assay device with sample extraction means
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US5434057A (en) 1994-02-02 1995-07-18 Quidel Corporation Sperm motility assay and devices
US5521102A (en) 1994-08-08 1996-05-28 Quidel Corporation Controlled sensitivity immunochromatographic assay
US5845255A (en) 1994-10-28 1998-12-01 Advanced Health Med-E-Systems Corporation Prescription management system
US6551593B1 (en) 1995-02-10 2003-04-22 Millennium Pharmaceuticals, Inc. Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
US5712172A (en) 1995-05-18 1998-01-27 Wyntek Diagnostics, Inc. One step immunochromatographic device and method of use
US5804452A (en) 1995-04-27 1998-09-08 Quidel Corporation One step urine creatinine assays
US5786220A (en) 1995-04-28 1998-07-28 Quidel Corporation Assays and devices for distinguishing between normal and abnormal pregnancy
US20010051350A1 (en) 1995-05-02 2001-12-13 Albert Nazareth Diagnostic detection device and method
US5773234A (en) 1995-08-07 1998-06-30 Quidel Corporation Method and device for chlamydia detection
DE19543553B4 (de) * 1995-11-22 2009-04-09 Deutsches Primatenzentrum Gmbh VP-Antigene des JC-Virus
US6305377B1 (en) 1996-12-12 2001-10-23 Michael T. Portwood System and method for improving compliance of a medical regimen
US6229011B1 (en) 1997-08-22 2001-05-08 Hoffman-La Roche Inc. N-aroylphenylalanine derivative VCAM-1 inhibitors
US6306642B1 (en) 1997-11-24 2001-10-23 Quidel Corporation Enzyme substrate delivery and product registration in one step enzyme immunoassays
US6623981B2 (en) 1998-01-27 2003-09-23 Bristol-Myers Squibb Company Detection of patients at risk for developing integrin antagonist/agonist mediated disease states
US6014631A (en) 1998-04-02 2000-01-11 Merck-Medco Managed Care, Llc Computer implemented patient medication review system and process for the managed care, health care and/or pharmacy industry
US6045501A (en) 1998-08-28 2000-04-04 Celgene Corporation Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug
US6407066B1 (en) 1999-01-26 2002-06-18 Elan Pharmaceuticals, Inc. Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4
US7171371B2 (en) 1999-09-03 2007-01-30 Smg Trust Method and system for providing pre and post operative support and care
ES2194782T5 (es) 1999-10-12 2014-08-20 Oxoid (Ely) Limited Procedimiento mejorado de detección de bacterias acidorresistentes del género Helicobacter en las heces
US6388084B1 (en) 1999-12-06 2002-05-14 Hoffmann-La Roche Inc. 4-pyridinyl-n-acyl-l-phenylalanines
DK2140881T3 (da) 1999-12-16 2013-05-06 Biogen Idec Inc Fremgangsmåder til behandling af iskæmisk eller hæmoragisk læsion i centralnervesystemet ved anvendelse af anti-alpha-4-integrin-antagonister
WO2001075449A1 (fr) 2000-03-30 2001-10-11 Nippon Kayaku Kabushiki Kaisha Technique d'investigation du cancer par epreuve biologique d'un autoanticorps contre mdm2 et reactif
US6620626B1 (en) 2000-08-09 2003-09-16 Mission Research Corp. Antigen detection device and method
MY129000A (en) 2000-08-31 2007-03-30 Tanabe Seiyaku Co INHIBITORS OF a4 MEDIATED CELL ADHESION
DK1340086T3 (da) 2000-10-17 2008-12-01 Besst Test Aps Assay til direkte detektion af en RS-virusrelateret biologisk celle i en legemsvæskepröve
US6315720B1 (en) 2000-10-23 2001-11-13 Celgene Corporation Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug
US6485460B2 (en) 2001-01-12 2002-11-26 Bracco Diagnostics, Inc. Tamper evident syringe barrel
AU2002331408B2 (en) * 2001-08-20 2008-05-08 Proteome Systems Ltd Diagnostic testing process and apparatus
WO2003016902A1 (en) 2001-08-20 2003-02-27 Proteome Systems Intellectual Property Pty Ltd Diagnostic testing process and apparatus
US6605602B1 (en) 2001-09-28 2003-08-12 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Method of treating BK virus nephropathy
ATE512163T1 (de) 2002-02-25 2011-06-15 Elan Pharm Inc Verabreichung von mitteln zur behandlung von entzündungen
TWI281470B (en) 2002-05-24 2007-05-21 Elan Pharm Inc Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins
TW200307671A (en) 2002-05-24 2003-12-16 Elan Pharm Inc Heteroaryl compounds which inhibit leukocyte adhesion mediated by α 4 integrins
WO2004001539A2 (en) 2002-06-21 2003-12-31 Mckesson Information Solutions Llc Closed loop medication use system and method
US20070275481A1 (en) 2003-11-24 2007-11-29 Biogen Idec Ma Inc. Methods For Detecting Half-Antibodies Using Chip Based Gel Electophoresis
JP4672263B2 (ja) 2004-01-27 2011-04-20 デンカ生研株式会社 簡便な検出法、検出装置及び検出キットとその製法
US7419666B1 (en) 2004-02-23 2008-09-02 Massachusetts Eye And Ear Infirmary Treatment of ocular disorders
TWI439284B (zh) 2004-04-09 2014-06-01 Abbvie Biotechnology Ltd 用於治療TNFα相關失調症之多重可變劑量療法
US20050283385A1 (en) 2004-06-21 2005-12-22 The Permanente Medical Group, Inc. Individualized healthcare management system
EA012433B1 (ru) 2004-07-08 2009-10-30 Элан Фармасьютикалз, Инк. Многовалентные vla-4 антагонисты, содержащие полимерные фрагменты
CA2478458A1 (en) 2004-08-20 2006-02-20 Michael Panzara Treatment of pediatric multiple sclerosis
CN101111263A (zh) 2004-12-03 2008-01-23 比奥根艾迪克Ma公司 推迟或阻止发生多发性硬化
US7972775B2 (en) 2005-03-03 2011-07-05 Seedlings Life Science Ventures, Llc Method of risk management for patients undergoing Natalizumab treatment
ES2536915T5 (es) 2005-04-04 2023-03-01 Biogen Ma Inc Métodos y productos para evaluar una respuesta inmunitaria a una proteína terapéutica
ATE493405T1 (de) 2005-09-29 2011-01-15 Elan Pharm Inc Pyrimidinylamidverbindungen, die die durch vla-4 vermittelte leukozytenadhäsion inhibieren
CN101389611B (zh) 2006-02-27 2012-07-18 伊兰制药公司 抑制由vla-4所介导的白血球粘附的嘧啶磺酰胺化合物
EP2676967B1 (en) * 2006-02-28 2019-08-14 Biogen MA Inc. Methods of treating inflammatory and autoimmune diseases with natalizumab
EP2007392A4 (en) 2006-02-28 2010-04-07 Elan Pharm Inc METHOD FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES WITH ALPHA-4-INHIBITABLE COMPOUNDS
EP3360900A1 (en) 2006-03-03 2018-08-15 Biogen MA Inc. Methods of treating inflammatory and autoimmune diseases with natalizumab
US7838583B2 (en) * 2006-06-30 2010-11-23 Sumitomo Rubber Industries, Ltd. Rubber composition for cap tread and pneumatic tire having cap tread using same
EP2089515A4 (en) * 2006-11-16 2011-02-23 Novavax Inc VIRUSUAL PARTICLES OF RESPIRATORY SYNZYTIAL VIRUS
EP1933140B1 (en) 2006-12-11 2011-08-17 AraGen Biotechnology Co. Ltd. Antibody detection method involving an oligonucleotide enhanced collodial gold signal
SG2014009120A (en) 2009-02-05 2014-03-28 Biogen Idec Inc Methods for the detection of jc polyoma virus
US9354233B2 (en) 2009-02-20 2016-05-31 The Regents Of The University Of California A+ biomarker assays
CN102906278A (zh) 2010-01-11 2013-01-30 比奥根艾迪克Ma公司 用于jc病毒抗体的测定
HUE043339T2 (hu) 2011-05-31 2019-08-28 Biogen Ma Inc Módszer a PML kockázatának megállapítására

Also Published As

Publication number Publication date
KR20120112621A (ko) 2012-10-11
FI3339865T5 (fi) 2023-04-15
FI4152004T3 (fi) 2025-02-21
MX341991B (es) 2016-09-09
BR112012017014A8 (pt) 2018-06-05
DK3339865T3 (da) 2022-11-28
PL2524060T3 (pl) 2018-05-30
SMT202200445T1 (it) 2023-01-13
IN2012DN06139A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2015-09-18
HRP20180356T1 (hr) 2018-04-06
EP3339865A1 (en) 2018-06-27
EP4152004A1 (en) 2023-03-22
KR101877576B1 (ko) 2018-07-12
LT2524060T (lt) 2018-03-26
SMT201800148T1 (it) 2018-05-02
ES2664173T3 (es) 2018-04-18
HRP20250210T1 (hr) 2025-04-11
SMT202500065T1 (it) 2025-03-12
PL4152004T3 (pl) 2025-03-24
HUE060312T2 (hu) 2023-02-28
EP4152004B1 (en) 2024-11-20
CY1119972T1 (el) 2018-12-12
RS56977B1 (sr) 2018-05-31
DK2524060T3 (en) 2018-03-12
LT4152004T (lt) 2025-02-25
EP3339865B1 (en) 2022-08-24
ES3012733T3 (en) 2025-04-10
LT3339865T (lt) 2022-12-12
BR112012017014B1 (pt) 2021-07-20
DK4152004T3 (da) 2025-02-24
AU2011203815A1 (en) 2012-07-05
US20160187337A1 (en) 2016-06-30
CN102906278A (zh) 2013-01-30
AU2011203815B2 (en) 2015-11-26
SI2524060T1 (en) 2018-05-31
JP2013516633A (ja) 2013-05-13
HUE036183T2 (hu) 2018-06-28
EP3339865B9 (en) 2022-12-14
EP4152004B9 (en) 2025-04-09
HUE070903T2 (hu) 2025-07-28
JP2016040557A (ja) 2016-03-24
EP4524571A2 (en) 2025-03-19
PT2524060T (pt) 2018-03-28
PL3339865T3 (pl) 2022-12-19
NZ600681A (en) 2014-10-31
JP5946218B2 (ja) 2016-07-05
CY1126069T1 (el) 2023-11-15
HK1255318A1 (en) 2019-08-16
PT4152004T (pt) 2025-02-18
BR112012017014A2 (pt) 2016-04-05
US20130022961A1 (en) 2013-01-24
RS63744B1 (sr) 2022-12-30
ES2930469T3 (es) 2022-12-14
EP4524571A3 (en) 2025-06-11
SG10201500079YA (en) 2015-03-30
RS66509B1 (sr) 2025-03-31
MX2012007660A (es) 2012-07-25
ME03026B (me) 2018-10-20
EP2524060B1 (en) 2017-11-29
US10444234B2 (en) 2019-10-15
SI4152004T1 (sl) 2025-04-30
EP2524060A4 (en) 2013-10-09
DK3339865T5 (da) 2023-03-20
NO2524060T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2018-04-28
CA2784137A1 (en) 2011-07-14
SI3339865T1 (sl) 2023-01-31
EP2524060A1 (en) 2012-11-21
HRP20221390T1 (hr) 2023-01-06
US9316641B2 (en) 2016-04-19
WO2011085369A1 (en) 2011-07-14
PT3339865T (pt) 2022-11-22
SG181653A1 (en) 2012-07-30

Similar Documents

Publication Publication Date Title
FI3339865T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP2013516633A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
Pratesi et al. Deiminated Epstein‐Barr virus nuclear antigen 1 is a target of anti–citrullinated protein antibodies in rheumatoid arthritis
JP5792626B2 (ja) 補体固定抗体の検出のための方法および組成物
JP2019535015A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP2020522685A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP2019530875A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP2020517919A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX2009013411A (es) Deteccion de antigenos transportados por eritrocitos y de anticuerpos anti-eritrocitos.
JP2012517017A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
US20140234877A1 (en) Method for detecting a beta-specific antibodies in a biological sample
Pohanka et al. Diagnosis of tularemia using piezoelectric biosensor technology
Seaman et al. Anti-peptidyl-arginine deaminase 3 (PAD3) antibodies as a promising marker to measure joint damage in patients with rheumatoid arthritis
FI3509624T3 (fi) Menetelmiä neutraloivien anti-leptiini -vasta-aineiden havaitsemiseksi
Cassaniti et al. Seroprevalence of SARS-CoV-2 in blood donors from the Lodi Red Zone and adjacent Lodi metropolitan and suburban area
Elfaitouri et al. Recent enterovirus infection in type 1 diabetes: evidence with a novel IgM method
JP2013506837A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO2011118982A3 (ko) 융합 폴리펩타이드 hpv 항원을 이용한 hpv 항체 스크리닝 방법
Kadkhoda COVID-19: how accurate are seroprevalence studies?
CN106771189B (zh) 一种油佐剂疫苗的快速定性定量检测方法
Stenberg et al. Early developing celiac disease in children with cerebral palsy
Yi et al. Impact of influenza virus escape‐mutations on influenza detection by the rapid influenza diagnostic test
JP6574119B2 (ja) ノロウイルス不活化評価方法
Groves et al. Rapid active assay for the detection of antibodies to West Nile virus in chickens
Fallahi et al. Virological and werological wurvey on bluetongue disease in sheep in some parts of Iran